Inflazome, acquired by Roche, generated three kinds of the compound with distinctive tissue distribution properties based on MCC950 [125]: inzomelid, a central nervous system (CNS) penetrant NLRP3 inhibitor, is being investigated for Alzheimer's disease, PD, cryopyrin-associated periodic syndrome, and amyotrophic lateral sclerosis; Somalix, a peripherally restricted NLRP3 inhibitor, is for cryopyrin-associated periodic syndrome; in addition, gut-restricted compounds are in development. Here, NLRP3 is linked to early-onset autosomal dominant Alzheimer disease.